Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Seattle Genetics has initiated a phase I/II clinical trial of its investigational compound SGN-40 in patients with chronic lymphocytic leukemia. This trial adds to the company's ongoing phase I trials with the drug in multiple myeloma and non-Hodgkin's lymphoma.
Subscribe to our email newsletter
The FDA has also granted orphan drug designation to SGN-40 for chronic lymphocytic leukemia (CLL) providing Seattle Genetics with seven years of marketing exclusivity in the event of market approval, as well as the opportunity to obtain grant funding from the US government. The drug has also been granted orphan drug designation in its multiple myeloma indication.
“We believe that SGN-40 may be an important therapeutic in the treatment of many types of B-cell malignancies,” stated Dr Clay Siegall, president and CEO of Seattle Genetics. “Initiating this clinical trial in CLL and receiving orphan drug designation are important accomplishments toward further expanding our opportunities for this program.”
The single-agent phase I/II study will evaluate the tolerability, pharmacokinetic profile and antitumor activity of a multi-dose regimen of SGN-40 in relapsed or refractory CLL patients. The study design allows rapid transition from the phase I dose-escalation portion into a phase II trial.
Seattle Genetics plans to enroll approximately sixty patients in the phase I/II study at multiple cancer centers in the US.